Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
183 hedge funds and large institutions have $1.16B invested in Eagle Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 60 reducing their positions, and 21 closing their positions.
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
40% more capital invested
Capital invested by funds: $832M → $1.16B (+$331M)
5% more funds holding
Funds holding: 174 → 183 (+9)
2% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $14.4M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$25.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$16.4M |
| 3 |
BlackRock
New York
|
+$11.5M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
+$10M |
| 5 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$5.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$22.2M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$20.5M |
| 3 |
First Eagle Investment Management
New York
|
-$17.3M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$16.8M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$11.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWP
201
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$29K | -550 | Closed |
|
|
GXMC
202
Global X Management Company
New York
| – | -$19K | -352 | Closed |
|
203
Group One Trading
Chicago,
Illinois
| – | -$12K | -190 | Closed |
|
EGRX Hedge Fund Activity: Q2 2018 in Review
183 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2018, worth a combined $1.16B — up 40% from $832M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new EGRX positions and 21 closed out — a net gain of 10 holders — while 57 added to existing stakes and 60 trimmed.
The largest buyer was Rothschild & Co Asset Management US, opening a new position worth an estimated $25.6M. The largest seller was Victory Capital Management, cutting an estimated $22.2M.
- 183 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2018, up from 174 in Q1 2018.
- Funds reported $1.16B of Eagle Pharmaceuticals, Inc. stock for Q2 2018, up 40% quarter-over-quarter.
- 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2018 and 21 closed out, a net change of +10 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2018 was Rothschild & Co Asset Management US, an estimated $25.6M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2018 was Victory Capital Management, an estimated $22.2M sold.
Based on aggregated 13F filings for Q2 2018.